{"altmetric_id":1827996,"counts":{"readers":{"mendeley":16,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":1,"unique_users":[55373],"posts_count":1},"total":{"posts_count":3},"twitter":{"unique_users_count":2,"unique_users":["FarmaOnco","emiliomonteb"],"posts_count":2}},"citation":{"abstract":"The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of ziv-aflibercept in combination therapy for metastatic colorectal cancer (mCRC) are reviewed.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f6100021fe","authors":["Clement Chung","Nisha Pherwani"],"doi":"10.2146\/ajhp130143","first_seen_on":"2013-10-15T19:42:57+00:00","issns":["1535-2900"],"journal":"American Journal of Health-System Pharmacy","last_mentioned_on":1381878780,"links":["http:\/\/www.ajhp.org\/content\/70\/21\/1887.abstract?rss=1","http:\/\/www.ajhp.org\/cgi\/content\/abstract\/70\/21\/1887"],"pdf_url":"http:\/\/www.ajhp.org\/content\/70\/21\/1887.full.pdf","pmid":"24128964","pubdate":"2013-01-01T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"subjects":["pharmacy","hospitals"],"title":"Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/zivaflibercept-novel-angiogenesis-inhibitor-treatment-metastatic-colorectal-cancer-1"},"altmetric_score":{"score":7.774,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7.774},"context_for_score":{"all":{"total_number_of_other_articles":7577422,"mean":6.5343911016651,"rank":974651,"this_scored_higher_than_pct":87,"this_scored_higher_than":6602725,"rank_type":"exact","sample_size":7577422,"percentile":87},"similar_age_3m":{"total_number_of_other_articles":140885,"mean":6.9349199199343,"rank":19374,"this_scored_higher_than_pct":86,"this_scored_higher_than":121469,"rank_type":"exact","sample_size":140885,"percentile":86},"this_journal":{"total_number_of_other_articles":1377,"mean":4.2374709302326,"rank":182,"this_scored_higher_than_pct":86,"this_scored_higher_than":1195,"rank_type":"exact","sample_size":1377,"percentile":86},"similar_age_this_journal_3m":{"total_number_of_other_articles":19,"mean":2.8166666666667,"rank":3,"this_scored_higher_than_pct":84,"this_scored_higher_than":16,"rank_type":"exact","sample_size":19,"percentile":84}}},"demographics":{"poster_types":{"member_of_the_public":2},"users":{"twitter":{"cohorts":{"Members of the public":2}},"mendeley":{"by_status":{"Researcher":4,"Student  > Doctoral Student":1,"Other":2,"Student  > Master":7,"Student  > Bachelor":1,"Lecturer > Senior Lecturer":1},"by_discipline":{"Medicine and Dentistry":13,"Chemistry":2,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"ES":1},"mendeley":{"EC":2}}},"posts":{"blogs":[{"title":"Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer","url":"http:\/\/sciencealerts.com\/stories\/2534932\/Zivaflibercept_A_novel_angiogenesis_inhibitor_for_the_treatment_of_metastatic_colorectal_cancer.html","citation_ids":[1827996],"posted_on":"2013-10-15T23:13:00+00:00","summary":"The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of ziv-aflibercept in combination therapy for metastatic colorectal cancer (mCRC) are reviewed.Ziv-aflibercept (Zaltrap, Regeneron Pharmaceuticals and sanofi-aventis) is a no","author":{"name":"Science Alerts Social Network","url":"http:\/\/sciencealerts.com\/","description":"Science Alerts Social Network"}}],"twitter":[{"url":"http:\/\/twitter.com\/FarmaOnco\/status\/390200844043685888","license":"public","citation_ids":[1827996],"posted_on":"2013-10-15T19:41:45+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1674},"tweet_id":"390200844043685888"},{"url":"http:\/\/twitter.com\/emiliomonteb\/status\/390231887131979776","license":"public","citation_ids":[1827996],"posted_on":"2013-10-15T21:45:06+00:00","author":{"name":"Emilio Monte","url":"https:\/\/www.linkedin.com\/in\/emilio-monte-boquet-67032624\/","image":"https:\/\/pbs.twimg.com\/profile_images\/898548741422153728\/en1Mia9R_normal.jpg","description":"#Farmacia #HospitalLaFe #HospitalPharmacy PharmD PhD #eSalud #eHealth #Sherpas20 @ufpelafe @eDruida_","id_on_source":"emiliomonteb","tweeter_id":"51391835","geo":{"lt":39.5,"ln":-0.75,"country":"ES"},"followers":3631},"tweet_id":"390231887131979776"}]}}